NASDAQ$IRMD
IRadimed Corporation · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported record revenue and GAAP diluted EPS for the third quarter of 2024.
IRADIMED CORPORATION announced record revenue of $18.3 million for Q3 2024, an 11% increase compared to Q3 2023. GAAP diluted EPS was reported as $0.40 and Non-GAAP diluted EPS as $0.43. The company is raising year-end guidance on GAAP diluted earnings per share to $1.49 to $1.52 and Non-GAAP diluted earnings per share to $1.64 to $1.67.
- Record revenue of $18.3 million for the third quarter of 2024, an 11% increase year-over-year.
- GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.
- Year-end guidance raised for GAAP diluted earnings per share to $1.49-$1.52 and Non-GAAP diluted earnings per share to $1.64-$1.67.
- Declared a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024.
Headline financials
Revenue & EPS history
IRadimed · Revenue · Quarterly
$18.3M
Forward guidance
For Q4 2024, IRADIMED anticipates revenue between $18.8 million and $19.2 million, GAAP diluted earnings per share of $0.39 to $0.42, and Non-GAAP diluted earnings per share of $0.42 to $0.45. For the full year 2024, revenue is expected to be $72.7 million to $73.1 million, with GAAP diluted earnings per share of $1.49 to $1.52, and Non-GAAP diluted earnings per share of $1.64 to $1.67.
Tailwinds
- Revenue is expected to be between $18.8 million and $19.2 million for Q4 2024.
- GAAP diluted earnings per share are projected to be $0.39 to $0.42 for Q4 2024.
- Non-GAAP diluted earnings per share are anticipated to be $0.42 to $0.45 for Q4 2024.
- Full-year 2024 revenue is forecasted to be $72.7 million to $73.1 million.
- Full-year 2024 GAAP diluted earnings per share are expected to be $1.49 to $1.52.
Headwinds
- Stock-based compensation expense, net of tax, is expected to be approximately $0.5 million for Q4 2024.
- Construction continues on the Company’s new facility in Orlando, Florida, and the Company anticipates spending approximately $9 million in cash, as of September 30, 2024, to complete it.
- Potential disruptions in the limited supply chain for our products.
- The Company’s ability to receive U.S. Food and Drug Administration (“FDA”) 510(k) clearance for new products and product candidates
- Unexpected costs, delays or diversion of management’s attention associated with the design, manufacturing or sale of new products
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+2.2%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.8%
Avg return
30 days after
59%
30 / 51 earnings
Positive
+32.1%
Q2 2019
Best reaction
-20.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | +3.4% | +8.6% | |
| Q4 2025 | +9.6% | +4.0% | +3.5% | |
| Q3 2025 | +9.4% | +9.8% | +21.3% | |
| Q1 2025 | -2.3% | -3.0% | +13.7% | |
| Q4 2024 | -8.4% | -5.8% | -13.3% | |
| Q3 2024 | -8.8% | -0.4% | +1.9% | |
| Q2 2024 | -4.9% | -6.6% | +0.5% | |
| Q1 2024 | +6.4% | +4.0% | +1.1% | |
| Q4 2023 | -6.9% | -3.3% | -5.2% | |
| Q3 2023 | +3.5% | -1.3% | +3.5% | |
| Q2 2023 | +10.7% | +10.4% | +9.7% | |
| Q1 2023 | +8.5% | +8.3% | +13.0% | |
| Q4 2022 | +10.1% | -0.3% | +3.7% | |
| Q3 2022 | +5.2% | +6.0% | +9.4% | |
| Q2 2022 | -1.4% | -3.2% | -17.8% | |
| Q1 2022 | -17.2% | -21.5% | -19.4% | |
| Q4 2021 | +19.8% | +33.5% | +24.1% | |
| Q3 2021 | +6.4% | +5.1% | +16.8% | |
| Q2 2021 | +1.0% | -1.8% | -2.2% | |
| Q1 2021 | +5.9% | +9.2% | +3.9% | |
| Q4 2020 | -7.2% | -2.4% | -7.8% | |
| Q3 2020 | +3.1% | +2.7% | +9.0% | |
| Q2 2020 | -4.2% | -2.7% | -7.2% | |
| Q1 2020 | -7.9% | -8.4% | +8.1% | |
| Q4 2019 | +2.4% | -0.5% | -10.8% | |
| Q3 2019 | +5.5% | +1.9% | -8.2% | |
| Q2 2019 | +32.1% | +23.6% | +7.1% | |
| Q1 2019 | -20.0% | -15.1% | -25.3% | |
| Q4 2018 | -0.4% | -0.9% | -12.4% | |
| Q3 2018 | +1.7% | +4.8% | +16.1% | |
| Q2 2018 | +4.6% | +9.8% | +17.5% | |
| Q1 2018 | +13.6% | +15.1% | +17.0% | |
| Q4 2017 | -6.3% | -7.3% | -13.6% | |
| Q3 2017 | +12.2% | +7.1% | +11.0% | |
| Q2 2017 | +17.3% | +14.9% | +18.5% | |
| Q1 2017 | -3.4% | -3.4% | -6.2% | |
| Q4 2016 | -4.0% | -2.8% | -2.8% | |
| Q3 2016 | +2.2% | +0.5% | +22.7% | |
| Q2 2016 | +2.8% | -4.6% | -1.2% | |
| Q1 2016 | -5.6% | — | — | |
| Q4 2015 | -17.1% | — | — | |
| Q3 2015 | +11.6% | — | — | |
| Q1 2014 | +0.2% | — | — | |
| Q2 2015 | +18.6% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +7.2% | — | — | |
| Q3 2013 | +4.9% | — | — | |
| Q3 2014 | +4.9% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q2 2013 | -2.3% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro